J and J wants the strip business and want no competition and Decision Diagnostics countered with J&J advertising that the One Touch system provides more accurate results than other companies. Genstrip is the name of the testing strips. The article here suggests that J&J could buy them up and get rid of the competition, and I guess court costs versus loss of business will some influence on what happens here.
We used to hear about the J&J stent wars and now we are down to stick wars (glucose strips), but there’s a lot of money in those strips. Before my mother passes away who was a diabetic the mail order pharmacies are all over get those out and even over supplying at times. BD
With more than 250 units making and marketing therapeutic products worldwide, Johnson & Johnson JNJ +0.79% (JNJ) is one of the most diversified global healthcare companies. And as a leader in pharmaceuticals, medical devices, and consumer personal-care products, the company not surprisingly makes sure it adequately protects its turf.
Of late, its largest division, the medical device and diagnostic operations that generates some 40% of the company’s total sales, has been a focus of some of its attention. In particular, it’s defending its product called Lifescan Ultra, used for glucose monitoring in diabetes patients, which is estimated to be a $10 billion market. Right now, J&J dominates the market for single-use strips necessary for patients to use the Lifescan Ultra diagnostic device to check their glucose levels.
J&J, the largest player in this market, filed in September 2011 a patent infringement suit against a small company called Decision Diagnostics and sought an injunction to stop the company from selling its product named Genstrip, an alternative glucose testing strip designed specifically for use with Lifescan Ultra meters.